LLY is trading at $1045.85 (-3.19%) following reports of a 4% drop linked to competitor Novo Nordisk launching its obesity pill in the U.S., intensifying rivalry in the weight-loss drug market.
- Recent pipeline concerns are adding pressure, specifically regarding weak data for Eli Lilly's orforglipron pill.
- The orforglipron study results showed high drop-out rates and inferior weight loss compared to rival treatments.